Thirty-two cats with effusive or non-effusive feline infectious peritonitis treated with a combination of remdesivir and GS-441524
.jpg)
Thirty-two client-owned cats diagnosed with effusive or non-effusive FIP were retrospectively included.
GS-441524 has been successfully used to treat feline infectious peritonitis (FIP) in cats. However, the use of its prodrug, remdesivir, in combination with a PO GS-441524 containing product for the treatment of FIP has not yet been described. Tha aim of this study wa to describe treatment protocols, response to treatment and outcomes in cats with FIP treated with a combination of PO GS-441524 and injectable remdesivir.
Thirty-two client-owned cats diagnosed with effusive or non-effusive FIP, including those with ocular and neurological involvement, were retrospectively included.
Cats received treatment with different combinations of IV remdesivir, SC remdesivir, and PO GS-441524 at a median (range) dosage of 15 (10-20) mg/kg. Clinical response to treatment was observed in 28 of 32 cats (87.5%) in a median (range) of 2 (1-5) days. Twenty-six of 32 cats (81.3%) were alive and in clinical and biochemical remission at the end of the 12-week treatment period. Six of 32 cats (18.8%) died or were euthanized during treatment with 4 of the 6 cats (66%) dying within 3 days of starting treatment.
In conclusion, this study describes the effective use of injectable remdesivir and PO GS-441524 for the treatment of FIP in cats.
“Thirty-two cats with effusive or non-effusive feline infectious peritonitis treated with a combination of remdesivir and GS-4415242” Jodie Green, et al. J Vet Intern Med. 2023 Jul 4. doi: 10.1111/jvim.16804.
Comments
Related Articles
Copyright © 2025 - All Rights Reserved
ISSN 2768-198X
List
Add
Please enter a comment